Last Updated: November 18, 2026

GEMTESA Drug Patent Profile

« Back to Dashboard


When do Gemtesa patents expire, and when can generic versions of Gemtesa launch?

Gemtesa is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in GEMTESA is vibegron. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the vibegron profile page.

DrugPatentWatch® Generic Entry Outlook for Gemtesa

Gemtesa was eligible for patent challenges on December 23, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for GEMTESA?
  • What are the global sales for GEMTESA?
  • What is Average Wholesale Price for GEMTESA?
Summary for GEMTESA
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GEMTESA
Generic Entry Date for GEMTESA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GEMTESA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPHASE3
University of Missouri-ColumbiaEARLY_PHASE1
Urovant Sciences GmbHPhase 4

See all GEMTESA clinical trials

Pharmacology for GEMTESA
Paragraph IV (Patent) Challenges for GEMTESA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GEMTESA Tablets vibegron 75 mg 213006 4 2024-12-23

US Patents and Regulatory Information for GEMTESA

GEMTESA is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of GEMTESA is ⤷  Start Trial.

This potential generic entry date is based on patent 8,653,260.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sumitomo Pharma Am GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes 12,102,638 ⤷  Start Trial ⤷  Start Trial
Sumitomo Pharma Am GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sumitomo Pharma Am GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes 8,247,415 ⤷  Start Trial Y Y ⤷  Start Trial
Sumitomo Pharma Am GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes 12,357,636 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for GEMTESA

When does loss-of-exclusivity occur for GEMTESA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2043
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 09231714
Estimated Expiration: ⤷  Start Trial

Austria

Patent: 35521
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 0909768
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 19876
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 09000815
Estimated Expiration: ⤷  Start Trial

China

Patent: 2056917
Estimated Expiration: ⤷  Start Trial

Patent: 2391255
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 31440
Estimated Expiration: ⤷  Start Trial

Costa Rica

Patent: 751
Estimated Expiration: ⤷  Start Trial

Patent: 120282
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0120129
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 12552
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 76756
Estimated Expiration: ⤷  Start Trial

Dominican Republic

Patent: 010000294
Estimated Expiration: ⤷  Start Trial

Patent: 013000267
Estimated Expiration: ⤷  Start Trial

Ecuador

Patent: 10010518
Estimated Expiration: ⤷  Start Trial

El Salvador

Patent: 10003687
Patent: HIDROXIMETIL PIRROLIDINAS COMO AGONISTAS DEL RECEPTOR ADRENERGICO BETA 3
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 0135
Estimated Expiration: ⤷  Start Trial

Patent: 1071169
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 76756
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 0240046
Estimated Expiration: ⤷  Start Trial

France

Patent: C1051
Estimated Expiration: ⤷  Start Trial

Georgia, Republic of

Patent: 0125666
Estimated Expiration: ⤷  Start Trial

Honduras

Patent: 10002030
Estimated Expiration: ⤷  Start Trial

Hong Kong

Patent: 47099
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 8215
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 83867
Estimated Expiration: ⤷  Start Trial

Patent: 83870
Estimated Expiration: ⤷  Start Trial

Patent: 32846
Estimated Expiration: ⤷  Start Trial

Patent: 11201897
Estimated Expiration: ⤷  Start Trial

Patent: 11510023
Estimated Expiration: ⤷  Start Trial

Patent: 12020961
Patent: HYDROXYMETHYL PYRROLIDINE AS β3 ADRENOCEPTOR AGONIST
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 10010929
Patent: HIDROXIMETIL PIRROLIDINAS COMO AGONISTAS DEL RECEPTOR ADRENERGICO BETA 3. (HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS.)
Estimated Expiration: ⤷  Start Trial

Montenegro

Patent: 988
Patent: HIDROKSIMETIL PIROLIDINI KAO AGONISTI BETA 3 ADRENERGIČKOG RECEPTORA (HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS)
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 257
Patent: هيدروكسيميتيل بيروليدين كمحفزات مستقبلات بيتا الأدرينالية-3.
Estimated Expiration: ⤷  Start Trial

Netherlands

Patent: 1305
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 8266
Patent: HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
Estimated Expiration: ⤷  Start Trial

Nicaragua

Patent: 1000164
Patent: HIDROXIMETIL PIRROLIDINAS COMO AGONISTAS DEL RECEPTOR ADRENÉRGICO BETA 3.
Estimated Expiration: ⤷  Start Trial

Norway

Patent: 24055
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 091825
Patent: HIDROXIMETIL PIRROLIDINAS COMO AGONISTAS DEL RECEPTOR ADRENERGICO BETA 3
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 76756
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 76756
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 175
Patent: HIDROKSIMETIL PIROLIDINI KAO AGONISTI BETA 3 ADRENERGIČKOG RECEPTORA (HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS)
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 8883
Patent: HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 76756
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1006720
Patent: HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1288798
Estimated Expiration: ⤷  Start Trial

Patent: 1331771
Estimated Expiration: ⤷  Start Trial

Patent: 100126860
Patent: Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Estimated Expiration: ⤷  Start Trial

Patent: 120104257
Patent: Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Estimated Expiration: ⤷  Start Trial

Patent: 120118086
Patent: HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 76278
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 0944521
Patent: Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Estimated Expiration: ⤷  Start Trial

Patent: 78098
Estimated Expiration: ⤷  Start Trial

Tunisia

Patent: 10000447
Patent: HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 1367
Patent: Normal;heading 1;heading 2;heading 3;HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GEMTESA around the world.

Country Patent Number Title Estimated Expiration
Australia 2018282104 ⤷  Start Trial
Australia 2024204591 ⤷  Start Trial
Brazil 112019025636 ⤷  Start Trial
Canada 3064989 UTILISATION DE VIBEGRON DANS LE TRAITEMENT DE LA VESSIE HYPERACTIVE (USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for GEMTESA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2276756 301305 Netherlands ⤷  Start Trial PRODUCT NAME: VIBEGRON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1822 20240628
2276756 CA 2024 00054 Denmark ⤷  Start Trial PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1822 20240628
2276756 LUC00366 Luxembourg ⤷  Start Trial PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1822 20240628
2276756 CR 2024 00054 Denmark ⤷  Start Trial PRODUCT NAME: VIBEGRON OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1822 20240628
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.